Literature DB >> 21963227

The phenotype of polycystic ovary syndrome ameliorates with aging.

Zoe A Brown1, Yvonne V Louwers, Sharon Lie Fong, Olivier Valkenburg, Erwin Birnie, Frank H de Jong, Bart C J M Fauser, Joop S E Laven.   

Abstract

OBJECTIVE: To assess the effects of aging on the features of polycystic ovary syndrome (PCOS).
DESIGN: Retrospective longitudinal follow-up study.
SETTING: Tertiary care center. PATIENT(S): Patients with PCOS, diagnosed according to the 2003 Rotterdam criteria, who visited the outpatient clinic on consecutive occasions with a minimum interval of 6 months. INTERVENTION(S): Comparisons were made between the first visit and the consecutive visit grouped by intervals. MAIN OUTCOME MEASURE(S): Changes in clinical and endocrine characteristics. RESULT(S): A total of 254 women visited the outpatient clinic on 2 occasions each. Consecutive visits were grouped into 0.5 to 3.9 years (n = 172; mean follow-up, 2.6 years) and 4.0 to 7.0 years (n = 82; mean follow-up, 5.5 years). At their second visit, significantly more women had regained a regular cycle. The total antral follicle count was similar. Serum levels of testosterone, androstenedione, and dehydroepiandrosterone sulfate had decreased significantly. Plasma glucose levels had increased, whereas serum insulin levels and homeostasis model assessment score had significantly decreased. CONCLUSION(S): The PCOS phenotype changed with aging, suggesting an amelioration of the phenotype and ovarian dysfunction as indicated by the increase in number of regular menstrual cycles, decrease in serum androgen levels, and decrease in insulin resistance.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963227     DOI: 10.1016/j.fertnstert.2011.09.002

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  33 in total

1.  Ovarian markers and irregular menses among women with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications study.

Authors:  C Kim; R S Miller; B H Braffett; Y Pan; V L Arends; A K Saenger; A Barnie; A V Sarma
Journal:  Clin Endocrinol (Oxf)       Date:  2018-01-26       Impact factor: 3.478

Review 2.  Polycystic ovary syndrome throughout a woman's life.

Authors:  José Bellver; Luis Rodríguez-Tabernero; Ana Robles; Elkin Muñoz; Francisca Martínez; José Landeras; Juan García-Velasco; Juan Fontes; Mónica Álvarez; Claudio Álvarez; Belén Acevedo
Journal:  J Assist Reprod Genet       Date:  2017-09-27       Impact factor: 3.412

Review 3.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

4.  Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program.

Authors:  Catherine Kim; Vanita R Aroda; Ronald B Goldberg; Naji Younes; Sharon L Edelstein; MaryLou Carrion-Petersen; David A Ehrmann
Journal:  J Clin Endocrinol Metab       Date:  2018-02-01       Impact factor: 5.958

Review 5.  Differential activity of the corticosteroidogenic enzymes in normal cycling women and women with polycystic ovary syndrome.

Authors:  Márcia Marly Winck Yamamoto; Sebastião Freitas de Medeiros
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

6.  Depression Over the Lifespan in a Population-Based Cohort of Women With Polycystic Ovary Syndrome: Longitudinal Analysis.

Authors:  Eleni A Greenwood; Kristine Yaffe; Melissa F Wellons; Marcelle I Cedars; Heather G Huddleston
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

Review 7.  Ontogeny of the ovary in polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Joanne S Richards
Journal:  Fertil Steril       Date:  2013-03-06       Impact factor: 7.329

8.  Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition.

Authors:  Alex J Polotsky; Amanda A Allshouse; Sybil L Crawford; Sioban D Harlow; Naila Khalil; Rasa Kazlauskaite; Nanette Santoro; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2014-02-11       Impact factor: 5.958

Review 9.  Longterm management of Polycystic Ovarian Syndrome (PCOS).

Authors:  Gordon W Bates; Richard S Legro
Journal:  Mol Cell Endocrinol       Date:  2012-12-20       Impact factor: 4.102

Review 10.  Polycystic ovary syndrome: current status and future perspective.

Authors:  Erin K Barthelmess; Rajesh K Naz
Journal:  Front Biosci (Elite Ed)       Date:  2014-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.